Discussion
CRISPR Therapeutics has launched a Phase 1 clinical trial to test its experimental cell therapy zugocabtagene geleucel (zugo-cel) in adults with relapsing neuromyelitis optica spectrum disorder (NMOSD), which means the disease is flaring. The Phase 1 study (NCT07804004) is also open to adults with other autoimmune conditions…